CAPA's Position on Biosimilars
Given that the data on biosimilars continues to increase as more come on the market, CAPA has updated its biosimilar position paper as of January 2018, and it can be found in English and French here:
Biosimilars (also known as Subsequent Entry Biologics or SEBs)
CAPA is continuously updating this page on biosimilars (also called subsequent entry biologics or SEBs). We have recently updated our position paper and also created a video to help you understand this type of medication.
CAPA's Video on Biosimilars
We have created the video below to help explain the different types of medications you may take to manage your arthritis. We encourage you to ask your healthcare providers questions about your medications to help you best manage your arthritis.
CAPA believes biosimilars are another important treatment option for patients, and we've explained the major differences between small molecule, biologic, and biosimilar drugs, too.
The Biosimilar Focus Group Project Report, The Arthritis Society (TAS), Mar 2017
On March 28, 2017, The Arthritis Society (TAS) released the findings of a national, collaborative focus group project designed to examine the patient perspective on biologics and biosimilars for people who live with one of six inflammatory diseases: ankylosing spondylitis, Crohn’s disease, psoriasis, psoriatic arthritis, rheumatoid arthritis and ulcerative colitis. This effort was led by TAS in collaboration with Canadian Arthritis Patient Alliance, Canadian Psoriasis Network, Crohn’s and Colitis Canada, and the Gastrointestinal Society. The findings highlighted the need for more patient education on biologics and biosimilars, as well as, treatment-decision support.
Here is a link to information on Health Canada's website about biosimilars. If you'd like to read more about terms and the regulations on biosimilars, click
videos have been provided by Amgen.
IAPO Biosimilar Toolkit
CAPA is a member of IAPO (the International Association of Patient Organizations), and IAPO has developed a lot of very good, easy to understand information on biosimilars. Explore the IAPO Biosimilar Toolkit.
BIOTECanada Cross Disciplinary Meeting on SEBs
On June 5, 2014, BIOTECanada, the national biotechnology industry association, hosted a cross disciplinary meeting attended by specialist physicians (dermatology, gastroenterololgy, nephrology, oncology and rheumatology), patients, patient group representatives and pharmacists, who discussed their thoughts about SEBs. A member of CAPA attended this meeting and provided the arthritis patients' point of view. BIOTECanada produced a discussion paper that outlines key areas identified by the meeting's attendees about consideration of SEBs as a part of provincial/ territorial formularies.